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Epidrugsto deacetylate histones and repress transcription, HDACs are a promising target
for therapy of human diseases. The class II HDACs are mainly involved in developmental and differentiation
processes, such as myogenesis. We report here that class I and class II HDAC inhibitors such as SAHA or the
class II selective inhibitor MC1568 induce down-regulation of class II HDACs in human cells. In particular,
both SAHA and MC1568 induce HDAC 4 down-regulation by increasing its speciﬁc sumoylation followed by
activation of proteasomal pathways of degradation. Sumoylation that corresponds to HDAC 4 nuclear
localization results in a transient increase of the HDAC 4 repressive action on target genes such as RARα and
TNFα. The HDAC 4 degradation that follows to its sumoylation results in gene target activation. Silencing of
the RANBP2 E3 ligase reverts HDAC 4 repression by blocking its own sumoylation. These ﬁndings identify a
crosstalk occurring between acetylation, deacetylation and sumoylation pathways and suggest that class II
speciﬁc HDAC inhibitors may affect different epigenetic pathways.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionChromatin represents a signal transducer that regulates genome
functions translating upstream signals into either transient or
permanent (and heritable) information. A large variety of incoming
signals induce complex patterns of enzyme-catalyzed modiﬁcations
such as phosphorylation, acetylation, ubiquitination, methylation,
ADP-ribosylation of DNA and/or histones. Chromatin-associated non-
histone proteins, signaling complexes and nuclear machineries are
also substrates for the above enzymes, but the functions of these
modiﬁcations are still largely elusive [1–4].
Emerging evidence suggests that epigenetic alterations of DNA and
chromatin are causally linked to oncogenesis and tumor progression,
and that chromatin regulators represent important targets for the
development of novel anti-cancer drugs [5–18]. This is true for both
the effectors of chromatin changes (e.g. histone and DNA modiﬁers),
and upstream signaling pathways.
Structural and/or functional alterations of histone acetyltransferases/
deacetylases (HATs or HDACs) have been documented in cancer:
aberrant chromatin recruitment of HDACs by various oncogenic fusion
proteins (PML-RAR, PLZF-RAR, AML1-ETO, TEL-AML1, and Bcl6) mis-
sense mutations, rearrangements or inactivation of CBP or p300 (HATs)39 0812144840.
l rights reserved.by oncogenic viral proteins [19–22]. In the best-documented cases,
deregulation of HATs or HDACs result in abnormal transcriptional
regulation of target genes relevant to the transformationprocess [23,24].
At the present, there are four classes of HDAC enzymes known. Class I
deacetylases include HDACs 1, 2, 3, and 8, related to yeast RPD3
deacetylase; class II deacetylases that include thosehomologous to yeast
HDA1, are divided into two subclasses, IIa (HDAC 4, 5, 7 and 9 and its
splice variant MITR) and IIb (HDAC 6, 10) [25–28]. HDAC 11 (class IV)
contains conserved residues in the catalytic core region shared by both
class I and II enzymes [29]. Like class I HDACs, members of the class II
family are also found in complexes with SMRT/N-CoR co-repressors.
Indeed, it has been suggested that deacetylase activity of HDAC 4 and 5
may arise from the class I HDAC 3 in SMRT/N-CoR containing HDAC
complexes. In contrast to class I HDACs, which are found almost
exclusively in the nucleus, class II enzymes are uniquely regulated by
nucleus–cytoplasm shuttling [30–32]. Whereas class IIa HDACs are
frequently considered redundant, it is likely that further studies may
reveal discrete biological functions speciﬁc for each family member.
Indeed, class II HDACs speciﬁcally interact with members of the human
myocyte enhancer factor 2 (MEF2) family of transcription factors and
with the 14-3-3 chaperone proteins in the control of myocyte
differentiation [33,34]. Whereas both class I and II HDACs share
homologies in their catalytic domain, class III HDACs are homologous
to the yeast SIR2 and do not show homologies to class I and II HDACs.
Mutations in HDAC genes have not been identiﬁed in human
malignancies, but multiple associations between HDACs and well-
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documented. Gene silencing by HDACs has been also identiﬁed in
the pathogenesis of certain leukemias [20,22] and in some types of
non-Hodgkin's lymphomas. Indeed in acute promyelocytic leukemia
(APL), the fusion protein PML-RAR-α recruits HDAC complexes to
repress transcription of RAR-regulated genes, causing a maturation
block in the myeloid cell line. Also in the t(8;21) acute myeloid
leukemia (AML) the chromosomal translocation produces an AML1-
ETO fusion protein that plays as potent dominant transcriptional
repressor through recruitment of HDAC complexes. HDAC inhibition
can relieve ETO-mediated transcriptional repression and induced
differentiation of the AML1-ETO cells.
It is now well-established that certain epigenetic drugs (“epi-
drugs”; e.g. HDAC inhibitors) [35,36] and NR ligands (e.g. ret(x)inoids)
are potent cancer-therapeutic and cancer-preventive agents [7–9,37–
43]. Recent studies have shown an unexpected convergence of the two
signaling paradigms: both activate the TNF-related apoptosis-inducing
ligand (TRAIL) pathway and TRAIL activation is, at least in part, the
cause of the tumor-selective action of HDACi's and retinoids [35–
37,41,42,44,45]. HDAC inhibitors and demethylating agents are in
multiple clinical trials to assess their activity on a variety of
hematopoietic and solid malignancies. Indeed, drugs that interfere
with the activity of DNA methyltransferases (demethylating agents)
display anti-tumor effects in vitro and synergizewithHDACi [15,35,46–
48]. A growing series of molecules has been designed to inhibit HDAC
and other epigenetic activities either globally or more speciﬁcally [49].
Indeed, chemically diverse agents have been discovered, including the
suberoylanilide hydroxamic acid (SAHA) [50,51]. SAHA binds directly
to theHDAC catalytic site, inhibits its enzymatic activity [52] and exerts
anti-proliferative and/or pro-apoptotic effects in transformed cells [8].
SAHA is bio-available and has objective evidence of anti-tumor activity
with a favourable side effect proﬁle in phase I and II clinical trials [53–
55]. All these observations strongly support the emergence of a novel
perspective in the developmentof cancer-therapeutic drugs that target
chromatinmodiﬁers through various routes with the aim of exploiting
more cancer-selective signaling pathways.
In the present manuscript, we studied the biological activity of pan
and class speciﬁcHDAC inhibitors in different cancermodels identifying
amechanismofHDAC4degradationmediated by SAHAor by the class II
selective inhibitor MC1568. We found that both SAHA and the class II
HDAC inhibitor MC1568 mediate HDAC 4 proteasomal degradation in
MCF7 breast cancer cells, by inducing its nuclear localization and
sumoylation mediated by the activity of the E3 ligase RANBP2.
2. Materials and methods
2.1. Chemicals
SAHA (Alexis Biochemicals) was prepared in 100% DMSO at the
concentration of 5×10−3M, stored at −20 °C and used at the dilution of
1:1000. VPA (Sigma) was used at the ﬁnal concentration of 10−3 M;
MS275 (Schering AG) was initially dissolved in 100% DMSO at the
concentration of 5×10−2 M; then a stock solution at the concentration
of 5×10−3M was prepared in 10% DMSO, 90% ethanol and used at the
dilution of 1:1000 in the experiments. The class speciﬁc compound,
MC1568 [49], was resuspended in DMSO and used at the ﬁnal
concentration of 5×10−6M. The cell-permeant proteasome inhibitors,
MG-132 and lactacystin, were purchased from Alexis Biochemicals.
The caspase inhibitor ZVAD was purchased from RD.
2.2. Cell cultures
Human breast carcinoma cell lines (ZR-75.1 and MCF-7), colon
cancer (Caco-2) and osteosarcoma (U2OS) cells were maintained in
Dulbecco'smodiﬁed Eagle'smedium (DMEM—Sigma); prostate cancer
(LnCap) and leukemia (U937) cell lines were grown in RPMI1640medium (Sigma). All cells were supplemented with 10% foetal bovine
serum, 2 mM glutamine and 100 U/ml penicillin/streptomycin. All cell
lines were maintained at 37 °C in a humidiﬁed atmosphere of 95% air,
5% CO2. COS cells were cultured as previously reported [56].
2.3. Transfections
The MCF7 cells were transfected with lipofectamine (GIBCO) as
indicated by suppliers. Brieﬂy, MCF7 cells have been plated at 90%
conﬂuence and transfected with 4 µg of plasmids (pSuper-RanBP2 and
pSuper-EMPTY,were kindly provided byM. Fornerod, TheNetherlands
Cancer Institute, NL). For the HDAC 4 knockdown experiments, MCF7
cells were transfected with 50 nM of siRNA directed against HDAC 4
(S18839) orwith the negative control siRNA (AM4611), both purchased
byAmbion. After 48 h, RNAwas extracted. Cos1 cells plated at a density
of 105 cells per well of 24-well plates were transfected by calcium
phosphate method [56]. Precipitates contained: 100 ng of RARE-tk-luc
or TNF-luc or ΔNF-kB-TNF-luc (kindly provided by D. Joyce, University
ofWestern Australia, AU); 20 ng of hRARα or 20 ng (1×), 40 ng (2×) and
160 ng (4×), 200 ng (5×) of HDAC 4 sumoylation mutant (kindly
provided by E. Jaffray, University of St. Andrews, UK) and 50 ng of
cytomegalovirus-β-galactosidase (CMV-β-Gal, used as an internal
control to normalize variations in the transfection efﬁciency). The
total quantity of DNAwas adjusted at 1 µg with pBluescript. Luciferase
were measured using standard protocols with the TECAN inﬁnite 200.
For the experiments shown in Fig. 4D (bottom panel), MCF7 cells have
been ‘nucleofected’ with the HDAC 4 sumoylation mutant (kindly
provided by E. Jaffray, University of St. Andrews, UK) as indicated by
suppliers (AMAXA). Brieﬂy, the cells have been harvested by
trypsinization and counted. The required number of cells (2×106
cells/nucleofection) was centrifuged at 1200 rpm for 5 min. The
supernatant was discarded and the pellet was resuspended in the Cell
Line Nucleofector™ Solution V to a ﬁnal concentration of 2×106 cells/
100 µl. 1 µg of DNA was added and the sample was transferred into a
cuvette, inserted the into the cuvette holder selecting the program
P-20 (for high transfection efﬁciency). Transfection efﬁciency was
measured as about 75%.
2.4. FACS analysis of apoptosis and cell cycle
Adherent and supernatant cells were harvested, and cells resus-
pended in staining solution containing RNAse A, propidium iodide
(50 µg/ml), sodium citrate (0.1%), NP40 (0.1%) in PBS 1X for 30 min in
the darkness. Cell cycle distribution was assessed with a FACScalibur
ﬂow cytometer (Becton Dickinson) and 10,000 cells were analyzed by
ModFit version 3 Technology (Verity) and Cell Quest (Becton
Dickinson). Apoptosis was quantiﬁed by propidium iodide/Annexin V
double staining (Roche) according to standard procedures [41].
2.5. Western blotting analysis and antibodies
For immunoblotting, cells were lysed (50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% NP40, 10 µM NaF, 0.1 mM Na3VO4), 40 µg/ml PMSF
and protease inhibitors (SIGMA). Insoluble material was removed by
centrifugation, and protein concentration was determined by Bio-Rad
assay (Biorad). Lysates (30 µg protein) were loaded onto SDS-PAGE
minigels and proteins were transferred to nitrocellulose membranes
(Schleicher and Schuell, Dassel, Germany) and recognized by speciﬁc
antibodies. The antibodies against HDAC 1 (1:1000), HDAC 2 (1:1000),
HDAC 3 (1:100), HDAC 5 (1:500) were purchased from Alexis
Biochemicals. The HDAC 4 (1:500) antibody was purchased from
SIGMA and the anti-HDAC 7 (1:1000) antibody from Cell Signalling
Technology. The α-tubulin (1:1000) and anti-His antibodies were
acquired from SIGMA; p21 Cip1/Waf1 (1:500) from BD Transduction
Laboratories. Primary antibodies were detected using horseradish
peroxidase-linked anti-mouse or anti-rabbit (Amersham Biosciences),
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system (Amersham Biosciences).
2.6. Rnase protection assay
The Ribonuclease (Rnase) Protection Asssay was performed
according to standard procedures (Pharmingen, San Diego, California)Fig. 1. Analyses of cell cycle and apoptosis in different cancer cell lines after treatment with S
after treatment at 0 h, 24 h and 36 hwith SAHA at the concentration of 5 µM; (B) Apoptotic as
the concentration of 5 µM; (C) Western blot analysis of p21 expression after 24 h of treatmand as reported previously [41]. For hybridization 6 µg of total RNA
were used and from 6 to 8×105 cpm/µl of labeling probe. These
fragments were recovered by ethanol precipitation and analyzed by
electrophoresis on a sequencing gel (5% of urea-polyacrylamide-bis-
acrylamide). The gel, after the drying process, was placed in contact
with a autoradiograﬁc ﬁlm (Hyperﬁlm-MP, Amersham). The exposure
time was O.N. The presence of the target mRNA in the samples isAHA. (A) Analysis of cell cycle in the ZR75.1, LNCAP, U2OS, MCF7, CACO-2, U937 cell lines
say in ZR75.1, LNCAP, U2OS, MCF7, CACO-2, U937 at 0 h, 24 h, 36 h and 48 hwith SAHA at
ent with 5 µM SAHA in CACO-2, ZR75.1, MCF7, U2OS, U937 cells.
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probe. Probes used for speciﬁc HDAC detection are available upon
request.
2.7. Immunoprecipitation assay (IP)
Cell extracts were prepared from pellets of ZR-75.1 cells to 80%
conﬂuence in 150-mm tissue culture plates. Proteins were extracted in
buffer containing NP-40 (0.5%), Tris–HCl pH 8.0 (20 mM), 150 mM
NaCl, PMSF (1 mM), Glycerol 10%, EDTA (1 mM) and 1×Complete
protease inhibitor mixture (SIGMA) for 20 min on ice. Cell debris was
removed by centrifugation for 10 min 12,000×g and the soluble
material was incubated with the antibodies against HDAC 4 (Sigma)
and HDAC 1 (Abcam) at the recommended concentrations over night a
4 °C. The immune-complexes were precipitated with Sepharose-
protein A/G Plus (Santa Cruz Biotechnology) for an additional 2 h at
4 °C. After four washes in lysis buffer and two in PBS, the proteins
bound to beads were used for HDAC assays or resuspended in SDS-
PAGE sample buffer and analyzed by Western blotting to verify
speciﬁc IP.
2.8. HDAC assay
We analyzed the HDAC activity (Upstate) in samples immunopre-
cipitated with HDAC 4, HDAC 1 and with non-speciﬁc IgG as negative
control. HDAC assays have been performed in the absence or presence
of HDACs inhibitors at the indicated concentrations.
2.9. RT-qPCR
Total RNAwas prepared using the TRIZOL reagent (Invitrogen) and
reverse-transcribed with oligo-(dT) primer and Suprescript II ReverseFig. 2.HDAC expression analysis after treatmentwith 5 µM SAHA. (A)Western blot analysis fo
analysis of HDAC 1, 2, 3, 4, 5, 6, 8 after treatment at 37 h with 5 µM SAHA; (C) Western blot an
absence of MG132 and Lactacystin at the indicated time points; (D) Immunoprecipitation
treatment with 5 µM SAHA and MC1568.Transcriptase (Invitrogen). For the qPCR a commercial kit (Quiagen)
and the following primers were used : for IRF1: forward: GCAGGCCCT-
GACTCCAGCAC; reverse: TGCCACTCCGACTGCTCCAA; for TNFα: forward:
CCTTGGTCTGGTAGGAGACG; reverse: CAGAGGGAAGAGTTCCCCAG; for
RANBP2: forward: GTCAGTCGGAACCCAGTCAG; reverse: TCCAA-
CACCGCGCTCCTTCC; for GADPH: forward: GTCAGTGGTGGACCTGACCT;
reverse: AGGGGAGATTCAGTGTGGTG; for HDAC 4: forward: TTTGCCCC-
GGATGTGGTGCT; reverse: TTCCGAGGCGTCGCAAATGG.
2.10. Chromathin IP
ChIP assays have been carried out as previously described [57].
2.11. Nuclear–cytoplasm extraction
MCF7 cells were washed with ice-cold sterilized PBS 1X with
Phosphatase Inhibitor Buffer (0.5 ml PIB/10 ml PBS) (PIB 125 mM NaF,
250 mM β-glycerophosphate, 250 mM para-nitrophenyl phosphate
(PNPP), 25 mM NaVO3). Later 10 ml ice-cold PBS/PIB were added and
the cells were scraped, transferred into a pre-chilled 15 ml tube and
spinned at 300×g for 5min at 4 °C. The pellet was resuspended in 1ml
ice-cold Hypotonic Buffer HB pH 7.5 (20 mMHEPES pH 7.5, 5 mM NaF,
10 µM Na2MoO4, 0.1 mM EDTA). The cells were incubated on ice for
15 min. Later 50 µl 10% Nonidet P-40 (0.5% ﬁnal) was added and the
tube vortexed vigorously for 10 s. The homogenate was centrifuged for
30 s at 4 °C. The supernatant (cytoplasmic fraction) was removed and
stored at −80 °C. The nuclear pellet was resuspended in 50 µl Lysis
Buffer AM1 (Active Motif) and incubated at 4 °C for 30 min on a
shaking platform. After a centrifugation for 10 min at 14,000×g at 4 °C
the supernatant (nuclear extract) was aliquoted and stored at −80 °C
to avoid freeze/thaw cycles. The protein concentration of the extract
was determined by using a Bradford-based assay.r the indicated HDACs after treatmentwith 5 µM SAHA in ZR75.1 and U2OS cells; (B) RPA
alysis for HDAC 4 expression in MCF7 cells after treatment with SAHA in the presence or
of HDAC 4 and detection with Sumo-1 and HDAC 4 in MCF7 cells after the indicated
Fig. 3. HDAC 4 and HDAC1 functional assay in ZR75.1. (A) HDAC1 and 4 enzymatic assay
in ZR75.1 after treatment with SAHA, MS275, VPA and selective Class 2 inhibitor
MC1568; (B) Western blot analyses of HDAC 4 expression upon treatment with 5 µM
MS275, 1 mM VPA and 5 µM MC1568 at the indicated time course; (C) Western blot
analysis of the expression levels of the HDAC 4 K559R sumoylationmutant inMCF7 cells
treated with 5 µM MC1568 for 48 h.
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3.1. The HDAC inhibitor SAHA induces a G2/M cell cycle block in cancer
cell lines of different origin
We investigated the effects of the class I–II HDAC inhibitor SAHA
(Merck) on cell cycle arrest and apoptosis in cancer cell lines asmodels
of different types of human cancer. To this aim, some epithelial cancer
cell lines such as breast (ZR75.1,MCF-7), prostate (LnCap) and intestine
(Caco-2) cancer cells, together with the osteosarcoma cell line U2OS
and the acute myeloid leukemia U937 cell line have been treated with
5 µM SAHA at the indicated time course (Fig. 1A) and cell cycle phases
have been analyzed. Although with some differences of sensitivity
(being the hematopoietic cells the most sensitive), all cancer cell lines
tested responded to SAHA stimulation with a G2-M block of cell cycle
andwith the induction of apoptosis (Fig.1B). Both apoptosis and G2-M
block resulted to be dose-dependent given that lower concentrations
of SAHA (1 and 2.5 µM) did not reach the same induction of
programmed cell death and resulted into a G1 block (data not
shown) instead of a G2/M of cell cycle. Moreover, in all the tested
cancer cells, p21WAF1/Cip1 induction was present upon SAHA stimula-
tion (Fig.1C) thus conﬁrming that p21 is a general target of the activity
of SAHA and that SAHA treatment had an impact at themolecular level.
Note that lower concentrations of SAHA able to induce a G1 but not a
G2/M block were still able to induce p21WAF1/Cip1(data not shown).
3.2. SAHA alters the expression levels of class II HDACs
In parallel to cell cycle and apoptosis assays, we veriﬁed the HDAC
expression levels byWestern blot analysis in two different cell lines, as
model of epithelial and connective cancers. To this aim, we used the
ZR75.1, as model of epithelial cancer, and the U2OS, as model of
sarcoma. As shown in Fig. 2A, HDAC 1, 2, 3 were very abundant and not
altered by SAHA treatment, whereas HDAC 4, 5 and 7, all members of
the class IIa HDACs, were generally expressed to a lower extent and
down-regulated by SAHA. The effect of HDAC 4, 5 and 7 down-
regulation appeared to be dose-dependent being delayed with lower
concentrations of SAHA (data not shown). The U937 cells taken as a
model of hematopoietic cancer minimally expressed class II HDACs
and did not express at all HDAC 4 (data not shown and [58]).
3.3. SAHA-dependent class II HDAC's down-regulation is
proteasome mediated
We reasoned that the effect of SAHA on class II HDACs might result
from a transcriptional down-regulation. To test this hypothesis, we
performedmultiple RNAse protection assays (RPA) to check HDAC 1, 2,
3, 4, 5, 6 and 8 mRNA expression in ZR75.1 breast cancer cells. As
shown in Fig. 2B, we did not detect any decrease in the mRNA levels of
these HDACs when compared to house keeping genes. HDAC 1, 2, 3
were more abundant than the other HDACs and HDAC 5 mRNA was
even up-regulated upon SAHA treatment. RPA analysis carried out in
U2OS cells fully conﬁrmed these results (data not shown). Note that
HDAC 7 mRNA expression levels have been evaluated separately by
quantitative PCR and did not display any change (data not shown). As a
second step, we postulated that SAHA down-regulation of class II
HDACs might be due to proteasomal activity. Such a mechanism has
been described for HDAC 2 with VPA treatment [59]. As it is shown in
Fig. 2C by Western blot analysis, treatment of MCF7 cells with 5 µM
SAHA decreases HDAC 4 expression. To assess whether HDAC 4 was
proteasome processed, we co-treated MCF7 cells with two different
proteasome inhibitors (MG132 5 µM and lactacystin 1 µM) and SAHA.
The expression levels of HDAC 4 that resulted stabilized, thereby
showing that HDAC 4 was proteosome processed upon SAHA
treatment in MCF7 cells. Given that HDAC 4 can be sumoylated, but
not ubiquitinated [60], we have assessed whether HDAC 4 wassumoylated upon SAHA treatment (Fig. 2D). Sumo 1 is immunopre-
cipitated with HDAC 4 in MCF7 cells upon treatment with SAHA or
with MC1568, a class II speciﬁc HDAC inhibitor, thus indicating that
sumoylation is involved in HDAC 4 deregulation (Fig. 2D).
3.4. The inhibitor MC1568 speciﬁcally regulates class II HDAC
expression levels
We postulated that the HDAC 4 down-regulation upon SAHA
treatment might be due to the inhibition of class II HDACs, reﬂecting a
situation inwhich a decreased class II HDAC expression level, accounts
for the speciﬁc enzymatic inhibition. To verify whether this effect
represents a general mechanism or a prerogative of SAHA, we tested
the activities of pan (SAHA), class I selective inhibitors (MS275, VPA)
and the recently identiﬁed class II inhibitor (MC1568) [49] on HDAC 1
and HDAC 4 immunoprecipitated from MCF7 cells (Fig. 3A). Whereas
SAHA clearly inhibits HDAC 1 and 4 activity, VPA and MS275 inhibit
HDAC 1, but not HDAC 4 that is instead blocked by the MC1568
inhibitor. Given that MC1568 is able to induce HDAC 4 down-
regulation in MCF7 cells (Fig. 3B) whereas VPA and MS275 do not
inﬂuence HDAC 4 expression levels (Fig. 3B), we concluded that HDAC
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HDAC inhibition (MC1568) in these cells. In full support of this
hypothesis, transfection of the speciﬁc sumomutant HDAC 4-K559R in
MCF7 cells fully abrogated HDAC 4 down-regulation by MC1568 thus
conﬁrming the role of HDAC 4 sumoylation in its degradation (Fig. 3C).
Moreover, the addition of the pan-caspase inhibitor ZVAD to MCF7
cells treated with SAHA or MC1568 did not alter HDAC 4 down-
regulation suggesting that this phenomenon occurs independently
from apoptosis (Supplementary Fig. 1).
3.5. HDAC 4 sumoylation mediates its repressive capacities whereas
HDAC 4 degradation results into a transcriptional activation stimuli
That HDAC 4 sumoylation regulates its enzymatic activity,
improving transcriptional repression has been shown [60] althoughFig. 4. Transcriptional activation by the class II HDAC inhibitor MC1568 on RARα and NF-KB.
the HDAC 4 sumoylation mutant K559R; (C, D) Analysis of TNFα and IRF1mRNA expression le
pol II occupancy on the IRF1 promoter after 96 h with MC1568; (F) Analysis of HDAC 4 mRNA
(G, H) Analysis of TNFα and IRF1 mRNA expression levels in MCF7 after transfection of siRNnot fully conﬁrmed [61]. Aiming to understand the role of HDAC 4
sumoylation and its degradation in our system, we transfected the
HDAC 4 sumoylation mutant (K559R) in COS cells and tested its
action on RARE-tk-luc and TNF-luc, transcriptional binding sites
accounting for RARα and NF-kB activity. Both RARα and NF-kB are
known to bind to HDAC 4 that regulates their transcriptional activity
[62–64]. Interestingly, the HDAC 4 sumoylation mutant was able to
induce activation of both RARE-tk-luc, and the TNF-luc in COS cells,
thus suggesting that the repressive capacities of HDAC 4 on RARα
and NF-KB (Fig. 4A, B) might be mediated by HDAC 4 sumoylation.
Interestingly when a mutant for the NF-kB binding site (Dnf-Kb) to
the TNF promoter was added, K559R-HDAC 4 was not able to induce
TNF-luc activation (Fig. 4B), thus suggesting a NF-kB dependent
activity of HDAC 4 repression. Since the K559R-HDAC 4 mutant
induced both RARE-tk-luc and TNF-luc when transfected in COS cells(A, B) Luciferase assay with TNF-luc and RARE-tk-luc after transfection of COS cells with
vels in MCF7 after 96 h of treatment with 5 µMMC1568; (E) Chromathin IP assay of RNA
expression levels in MCF7 cells after transfection of siRNA scrambled or against HDAC 4;
A scrambled or against HDAC 4.
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RARα and NF-kB target genes, such as IRF1 and TNFα, respectively.
Note, indeed, that HDAC 4 is normally present in the repressive
complex of both RARα and NF-KB [62–64]. After 96 h of treatment
with the MC1568, both IRF1 and TNFα were highly up-regulated, as
a positive effect of the complete degradation of HDAC 4 (Fig. 4C, D).
Accordingly, at the same time point, the IRF1 promoter analyzed by
ChIP assay, showed recruitment of the RNA POL II, thus conﬁrming
the transcriptional activation of the gene (Fig. 4E). Finally, siRNAs
against HDAC 4 (Fig. 4F) were able to up-regulate both TNFα and
IRF1 when transfected in MCF7 cells (Fig. 4G–H), thus conﬁrming the
repressive role of HDAC 4 in our system and the activation in the
absence of HDAC 4.Fig. 5. Transcriptional repression of the class II inhibitorMC1568 on RARα and NF-KB. (A) Ana
(B) Analysis of IRF1 mRNA expression in MCF7 cells after 48 h of treatment with 5 µM MC15
induction with MC1568; (D) HDAC localization after SAHA treatment in MCF7 cells; (E) RAN
RANBP2 knockdown in MCF7 cells treated with MC1568. (G) RT-qPCR analysis of IRF1 mRN3.6. HDAC 4 sumoylation is mediated by RANBP2 E3 ligase activity and is
able to repress HDAC 4 target genes
As here shown (Fig. 2D), we found that HDAC 4 was sumoylated
after 48 h of treatment with 5 µM MC1568 or 5 µM SAHA. To
strengthen the hypothesis of HDAC 4's sumoylation repressive role,
we assessed IRF1 and TNFα expression levels after 48 h of MC1568
treatment in MCF7 cells. Indeed, at this time point HDAC 4 is still
expressed and sumoylated (Fig. 2D). Note that in MCF7 cells already
after 40 h upon SAHA treatment, HDAC 4 translocated into the nuclei
(Fig. 5D). Both IRF1 and TNFαwere heavily repressed as shown by RT-
PqCR in Fig. 5A, B and as RNA pol II recruitment on the IRF1 promoter
(Fig. 5C). Nuclear localization of HDAC 4 has been reported to belysis of TNFαmRNA expression inMCF7 cells after 48 h of treatmentwith 5 µMMC1568;
68; (C) Chromatin IP assay for RNA Pol II occupancy on the IRF1 promoter after 48 h of
BP2 silencing efﬁciency evaluation by qPCR; (F) RT-qPCR analysis of TNFα mRNA after
A after RANBP2 knockdown in MCF7 cells treated with MC1568.
2037A. Scognamiglio et al. / Biochimica et Biophysica Acta 1783 (2008) 2030–2038involved in its sumoylation via the activity of RANBP2, a nucleoporin
with sumo-E3-ligase action [60]. Thus, we hypothesized that RANBP2
might regulate the repressive activities of HDAC 4 in this system.
RANBP2 knockdown inMCF7 cells by speciﬁc transfection a shRANBP2
(Fig. 5E–G) indicates that RANBP2 silencing is able on its own to
activate both IRF1 and TNFα, showing the involvement of RANBP2
into the regulation of their expression levels (Fig. 5F lane 4, Fig. 5G,
lane 4). Interestingly, RANBP2 knockdownwas fully able to reverse the
repression mediated by MC1568 (Fig. 5F, G) both on the IRF1 and
TNFα, clearly indicating that MC1568 is enhancing HDAC 4 sumoyla-
tion through the activity of RANBP2 sumo-E3-ligase. How RANBP2 is
than regulated by HDAC inhibitors in this system and whether
RANBP2 might be a target of acetylation still needs to be deﬁned.
4. Discussion
The role of HDACs in transcriptional repression and regulation
suggests the therapeutic potential of HDAC inhibitors and, more in
general, of epigenetic modulators in cellular systems in which the
HAT/HDAC's balance is altered. Indeed, HDAC inhibitors have a
promise for cancer therapy and a part of them are already in a clinical
trial for different types of diseases.We have shown here that the class I
and II HDAC inhibitor SAHA is a powerful inducer of growth arrest and
apoptosis in multiple cancer cells (Fig. 1A and B). Indeed, in all cancer
models used SAHA is able to induce the cell cycle inhibitor p21, a
known target of the activity of HDAC inhibitors together with a dose-
dependent G2-M cell cycle block (Fig. 1). Verifying the expression
levels of the most known HDACs, we found that members of the class
II HDACs 4, 5 and 7 had decreased expression upon SAHA treatment
whereas the HDAC 1, 2, 3 were unaltered. Moreover, this regulation
was similar in very different tumor types such as carcinomas and
sarcomas indicating a possible general mechanism of regulation
independent from the tissues examined. Those evidences prompt us
to postulate that a mechanism for HDAC inhibition could lead to the
decreased presence of the enzyme and, of consequence, to a decreased
activity. In logical terms, we investigated if this type of regulation
might be transcriptional or post-translational, ﬁnding that the
decreased expression level of class II enzymes (such as HDAC 4) are
due to a speciﬁc activation of protein degradation, independently from
the mRNA levels. In agreement with these ﬁndings, it has been
previously described a proteasome-dependent mechanism of HDAC 2
degradation in the presence of VPA [65]. Thereby, we postulated that
SAHA induction of HDAC 4 down-regulation might be linked with its
inhibitory activities. In this case, the presence/absence of the protein
would be the direct link to enzymatic function. Following our
hypothesis, SAHA might exert different levels of HDAC inhibition: it
might interfere with class I function without altering the protein
expression and, at the same time, destabilize the levels of class II
HDACs with a proteasome-dependent mechanism. In line with these
notions, the class II speciﬁc inhibitor MC1568, fully able to block HDAC
4 enzymatic function decreased HDAC 4 expression levels. This result
not only conﬁrmed that class II HDAC inhibition can be achieved by
deregulation of the protein, but indicates that i) the proposed
mechanism can represent a general feature for class II HDAC inhibition
in tumours; ii) the contemporaneous inhibition of class I HDACs is not
a necessary event to obtain class II HDAC inhibition; iii) the HDAC 4, 5
and 7 down-regulation may represent a mechanism to inhibit the
enzymatic activity by chemically different HDAC inhibitors. In terms of
function clearly HDAC 4 decrease leads to transcriptional activation of
target genes (Fig. 4), thus suggesting an indirect activating role for the
inhibitors used. Moreover, our data support a model in which HDAC 4
decrement is precisely regulated by RANBP2 sumoylation followed by
proteasomal degradation of the enzyme (Fig. 5). This concept high-
lights the complex interplay of pathways that occur upon treatment of
HDAC inhibitors in cancer cells indicating that a crosstalk between
acetylation and sumoylation may take part into the molecular effectsof HDAC inhibitors. Due to this interplay both repressive and
activating effects on HDAC target genes can be identiﬁed thus
identifying a scenario in which opposite HDAC roles are mediated by
the sumoylation (repressive) and by the proteasomal degradation
(activation) in function of the time of treatment. If these pathways are
cancer cell speciﬁc ormediated by selective acetylation of non-histone
targets stays to be deﬁned.
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